Search

Erasca Inc

Cerrado

14.09 -0.84

Resumen

Variación precio

24h

Actual

Mínimo

14.2

Máximo

14.59

Métricas clave

By Trading Economics

Ingresos

139M

-44M

BPA

-0.14

Empleados

103

EBITDA

139M

-43M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+69.3% upside

Dividendos

By Acuity

Próximas Ganancias

10 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1B

5.3B

Apertura anterior

14.93

Cierre anterior

14.09

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 sept 2026, 23:51 UTC

Australia's Inflation Rate Expected to Rise to 4.1% Amid Global Economic Pressures Ahead of September 30 Release

27 sept 2026, 23:51 UTC

China's Non-Manufacturing PMI set for release on September 30, with forecasts indicating continued economic contraction at 49.3 amid cautious market sentiment and geopolitical concerns.

27 sept 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI YoY data release on September 30, 2026, is crucial for understanding core inflation trends amid global economic uncertainties and potential interest rate impacts.

27 sept 2026, 23:51 UTC

Australia's Building Permits Expected to Decline 0.9% in August Amid Mixed Trends and Economic Uncertainty

27 sept 2026, 23:51 UTC

China's NBS Manufacturing PMI Set for Release on September 30, Forecasted at 50.1 Amid Concerns Over Economic Recovery and Global Trade Relations.

27 sept 2026, 23:41 UTC

Bank of Japan to Release Key Monetary Policy Minutes Amid Optimism and Inflation Concerns on September 27, 2026

27 sept 2026, 23:41 UTC

U.S. September 2026 Unemployment Rate Release Forecasts Slight Increase to 4.2%, Amid Cautious Market Sentiment and Economic Policy Discussions

27 sept 2026, 23:41 UTC

U.S. Average Hourly Earnings Expected to Rise 0.3% in September, Influencing Fed's Rate Hike Decisions Amid Inflation Concerns

27 sept 2026, 23:41 UTC

U.S. Non-Farm Payrolls Expected to Add 100K Jobs in September Amid Cautious Optimism and Potential Market Volatility

27 sept 2026, 23:41 UTC

U.S. Labor Force Participation Rate Release on October 2, 2026, Expected Amidst Cautious Sentiment and Economic Challenges

27 sept 2026, 23:41 UTC

US Average Hourly Earnings Report on October 2 Could Signal Fed Rate Hikes Amid Inflation Concerns and Market Volatility.

27 sept 2026, 23:11 UTC

S&P Global Manufacturing PMI for South Korea Expected to Show Slight Decline Amid Economic Pressures and Resilient Industries

27 sept 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 2.2% YoY Amidst Stabilizing Market Sentiment Despite Inflation Pressures

27 sept 2026, 23:11 UTC

Brazil's Industrial Production MoM Data Release on October 2, 2026: Market Anticipates Recovery Amid Ongoing Volatility.

27 sept 2026, 23:11 UTC

The EUR/CZK is trading roughly flat at the start of the new week, showing little change since Friday's close and reflecting stable performance.

27 sept 2026, 23:01 UTC

Correlated Moves
Macro News

The Russell 2000 Index is lower, continuing a decline from Friday's close, amid Boeing's software glitch concerns and ongoing U.S.-China tariff discussions.

27 sept 2026, 23:01 UTC

Correlated Moves
Macro News

The Nasdaq 100 Index is trading modestly lower amid reports of a U.S.-China tariff agreement on $30 billion in goods and geopolitical concerns.

27 sept 2026, 23:01 UTC

Macro News

The S&P 500 Index is trading lower amid macroeconomic developments, including the upcoming release of the Bank of Japan's July monetary policy minutes.

27 sept 2026, 23:01 UTC

Correlated Moves
Macro News

Silver prices fell modestly amid discussions on Iran's military readiness and the upcoming release of the Bank of Japan's policy meeting minutes.

27 sept 2026, 23:01 UTC

Macro News

The AUD/USD is slightly lower as trading resumes, positioned near the lower end of its one-month range amid upcoming Bank of Japan minutes.

27 sept 2026, 23:01 UTC

Macro News

Oil (WTI) is advancing modestly as tensions in the Middle East escalate, with Iran signaling a potential disruption to global oil supply routes.

27 sept 2026, 23:01 UTC

Correlated Moves
Macro News

Gold prices fell modestly, continuing a downward trend as geopolitical tensions and expectations of Bank of Japan minutes weigh on the market.

27 sept 2026, 23:01 UTC

Correlated Moves
Macro News

Platinum prices are declining, continuing a downward trend influenced by silver's drop and geopolitical tensions affecting global energy markets.

27 sept 2026, 23:01 UTC

Correlated Moves
Macro News

The Dow Jones Index is lower amid mixed U.S. equities, influenced by U.S.-China tariff discussions and geopolitical concerns over Iran.

27 sept 2026, 23:01 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% in August, Indicating Strong Business Confidence Amid Economic Uncertainties

27 sept 2026, 23:01 UTC

U.S. GDP Growth Rate for Q2 2026 Forecasted at 1.6% Amid Positive Foreign Investment and Trade Developments Ahead of September Release.

27 sept 2026, 23:01 UTC

U.S. GDP Price Index QoQ Final for Q2 2026 set to release on September 30, with a forecasted increase of 0.064%, amid positive market sentiment from U.S.-China trade negotiations aimed at reducing tariffs.

27 sept 2026, 23:01 UTC

PCE Price Index MoM for August 2026 set to release on September 30, with market expecting a 0.4% increase amid fluctuating inflation trends and rising foreign investment in U.S. equities.

27 sept 2026, 23:01 UTC

Upcoming PCE Price Index Release on September 30, 2026, May Influence U.S. Inflation Trends and Federal Reserve Policy Amid Mixed Market Sentiment.

27 sept 2026, 23:01 UTC

Personal Income MoM Data for August 2026 Forecasted to Rise by 0.4%, Indicating Cautious Optimism in U.S. Economic Growth Ahead of Release on September 30.

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

69.3% repunte

Estimación a 12 Meses

Media 24.125 USD  69.3%

Máximo 33 USD

Mínimo 20 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

6

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.